Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
NCT06988605 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2026-03-13
Summary
The main aim of the study is to assess real-world effectiveness of nemolizumab in Atopic Dermatitis (AD) as measured by physician assessment and patient reported outcome (PRO) in clinical practice at Month 6.
Conditions
Sponsors & Collaborators
-
Galderma R&D
lead INDUSTRY
Eligibility
- Min Age
- 12 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-14
- Primary Completion
- 2026-11-06
- Completion
- 2027-11-30
Countries
- United States
- Germany
- United Kingdom
Study Locations
More Related Trials
-
Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable
NCT05056779 ·Status: WITHDRAWN ·Phase: PHASE3
-
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
NCT03921411 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effects of Nemolizumab on Cytochrome P450 Substrates in Participants With Moderate-to-Severe Atopic Dermatitis
NCT04562116 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents With Moderate-to-Severe Atopic Dermatitis
NCT05990725 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.
NCT06899204 ·Status: RECRUITING
-
An Investigator-initiated Study of Apremilast to Demonstrate Efficacy Nummular Eczema
NCT03160248 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis
NCT02087943 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis
NCT05916365 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.
NCT04836858 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis
NCT01568489 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids
NCT06224348 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT04990440 ·Status: TERMINATED ·Phase: PHASE2
-
Lebrikizumab in Moderate-to-severe Atopic Dermatitis
NCT06906497 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06130566 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 2 Study of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT06058156 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis
NCT05155085 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)
NCT06181435 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis
NCT01756898 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis
NCT07220577 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema
NCT06807268 ·Status: RECRUITING ·Phase: PHASE3
-
Safety and Efficacy Study of ImCOOH Cream in Patients Suffering From Moderate Atopic Dermatitis
NCT00583895 ·Status: TERMINATED ·Phase: PHASE2
-
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
NCT06407934 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
NCT03569293 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis
NCT03831191 ·Status: TERMINATED ·Phase: PHASE2
-
Topical NF-kappaB Decoy in the Treatment of Atopic Dermatitis
NCT00125333 ·Status: COMPLETED ·Phase: PHASE1/PHASE2